Erythropoiesis-stimulating agents: Past and future

Kidney International

Volumn 72, Issue SUPPL. 107, 2007, Pages

  Nangaku, M ^a   Fliser, D ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chronic kidney disease; Darbepoetin; Erythropoietin; Hypoxia

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIESIS STIMULATING AGENT; ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANEMIA; ANGIOGENESIS; BLOOD BRAIN BARRIER; CARDIORENAL ANEMIA SYNDROME; CARDIOVASCULAR SYSTEM; CELL ACTIVITY; CELL MATURATION; CENTRAL NERVOUS SYSTEM; CHRONIC KIDNEY DISEASE; DRUG MECHANISM; EARLY DIAGNOSIS; ERYTHROPOIESIS; HEART FAILURE; HEART PROTECTION; HUMAN; KIDNEY; KIDNEY FAILURE; OBSERVATIONAL STUDY; PLEIOTROPY; POPULATION RESEARCH; PRIORITY JOURNAL; RENAL PROTECTION; SHORT SURVEY; STEM CELL; SYNDROME;

EID: 35348959993     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002480     Document Type: Editorial

References (30)

1. Nangaku M, Eckdardt KU. Pathogenesis of renal anemia. Semin Nephrol 2006; 26: 261-268.
2. Silverberg DS, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol 2006; 26: 296-306.
3. Iseki K, Kohagura K. Anemia as a risk factor for chronic kidney disease. Kidney Int (this issue).
4. Fliser D, Bahlmann FH, deGroot K, Haller H. Mechanisms of disease: erythropoietin - an old hormone with a new mission? Nat Clin Pract Cardiovasc Med 2006; 3: 563-572.
5. Fliser D, Bahlmann FH, Haller H. EPO: renoprotection beyond anemia correction. Pediatr Nephrol 2006; 21: 1785-1789.
6. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006; 70: 246-250.
7. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005; 293: 90-95.
8. Brines ML, Ghezzi P, Keenan S et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; 97: 10526-10531.
9. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001; 412: 641-647.
10. Grimm C, Wenzel A, Groszer M et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 2002; 8: 718-724.
11. Silverberg DS, Wexler D, Blum M et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003; 18: 141-146.
12. Silverberg DS, Wexler D, Blum M et al. The interaction between heart failure, renal failure and anemia - the cardio-renal anemia syndrome. Kidney Blood Press Res 2005; 28: 41-47.
13. Siems W, Carluccio F, Radenkovic S et al. Oxidative stress in renal anemia of hemodialysis patients is mitigated by epoetin treatment. Kidney Blood Press Res 2005; 28: 295-301.
14. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17: 17-25.
15. Kuriyama S, Tomonari H, Yoshida H et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-185.
16. Tapolyai M, Kadomatsu S, Perera-Chong M. r.hu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline. BMC Nephrol 2003; 4: 3.
17. Dean BB, Dylan M, Gano Jr A et al. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin 2005; 21: 981-987.
18. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66: 753-760.
19. Cody J, Daly C, Campbell M et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev 2005; 3: CD003266.
20. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
21. Singh SK, Szczech L, Tang KL et al. Correction of anemia with epoetin alpha in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
22. Ritz E, Laville M, Bilous RW et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 2007; 49: 194-207.
23. Leist M, Ghezzi P, Grasso G et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004; 305: 239-242.
24. Coleman TR, Westenfelder C, Togel FE et al. Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci USA 2006; 103: 5965-5970.
25. Imamura R, Isaka Y, Ichimaru N et al. Carbamylated erythropoietin protects the kidneys from ischemia-reperfusion injury without stimulating erythropoiesis. Biochem Biophys Res Commun 2007; 353: 786-792.
26. Eto N, Wada T, Inagi R et al. Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int; E-pub ahead of print.
27. Mitra A, Bansal S, Wang W et al. Erythropoietin ameliorates renal dysfunction during endotoxaemia. Nephrol Dial Transplant 2007; 22: 2349-2353.
28. Bahlmann FH, Kielstein JT, Haller H, Fliser D. Erythropoietin and progression of CKD. Kidney Int (this issue).
29. Katavetin P, Tungsanga K, Eiam-Ong S, Nangaku M. Antioxidative effects of erythropoietin. Kidney Int (this issue).
30. Aydin Z, Duijs J, Bajema IM, Van Zonneveld AJ, Rabelink TJ. Erythropoietin, progenitors, and repair. Kidney Int (this issue).